AstraZeneca has acquired a vaccine startup, providing the company with a simpler method for producing conjugate vaccines, according to BioPharma Dive. The report also mentions a psychedelic depression drug submission to the FDA and a sharp drop in shares for a biotech focused on autoimmune diseases.

The acquisition could influence how large pharma firms approach vaccine development and manufacturing efficiency. Senior leaders in pharma and biotech should consider how such deals may affect competitive positioning and technology adoption in vaccine pipelines.

A study cited by BioPharma Dive says that drug price increases in Germany could lead to higher costs for US patients. The report comes as tensions rise between the US and Germany over pharmaceutical pricing, with several large companies reducing their investments in Germany.

This development may affect global pricing strategies and investment flows for pharma firms. Senior executives should consider the risk of price changes in one market affecting costs and access in others, especially as regulatory pressures and market responses intensify.

Argenx will pay $550 million to acquire Unnatural Products’ macrocyclic peptide technology, according to BioPharma Dive. The platform is intended to help Argenx develop oral, durable medicines for serious immune-mediated diseases.

This move could influence how other pharma companies approach drug development for immune conditions. Senior executives should consider the implications for R&D investment and future competition in this space.

Regulators in the US have finalised a rule that will reduce payments for drugs provided under the 340B programme and introduce site-neutral payments in 2027, according to BioPharma Dive. Hospitals have strongly criticised the decision, which could affect their revenue streams.

This matters for healthcare executives, as the rule changes payment structures and may influence hospital budgets and drug contracting. Leaders in regulated sectors should monitor implementation and prepare for altered reimbursement models.

A US federal judge has ruled that Novo did not prove Lilly’s obesity drug ad campaign, which included claims of superiority, caused meaningful harm to Novo’s sales, according to BioPharma Dive. The decision means Novo’s request to block the ads was denied.

This case matters for pharma brand leaders as it shows the limits of legal action over competitor advertising. Courts may demand clear evidence of commercial harm before restricting rival marketing. Companies should assess how they substantiate claims of injury in future disputes.

Ferring will acquire Gameto, an IVF technology startup, in a deal worth up to $1.4 billion, according to BioPharma Dive. The buyout gives Ferring access to a technology that could make the in vitro fertilisation process less complex and demanding for patients.

This deal is notable for its size and focus on innovation in a tightly regulated industry. Senior executives in pharma and biotech should watch how this acquisition may shift the competitive field in IVF and influence future technology investments.

BioPharma Dive reports that a patient who received Bristol Myers' zola-cel, an autoimmune CAR-T therapy, died 44 days after treatment. In a separate move, Gilead has acquired a company for nearly $1.3 billion to challenge Johnson & Johnson's new psoriasis drug.

These developments raise concerns for pharma executives about the safety profile of advanced therapies and the competitive pressures in immunology. The death linked to zola-cel may prompt closer regulatory scrutiny, while Gilead's acquisition signals ongoing competition in the autoimmune market.

A new analysis from the non-profit ICER found that net launch prices for new medicines spiked significantly between 2022 and 2025, with most prices well above its cost-effectiveness guidelines, according to BioPharma Dive.

This trend puts additional scrutiny on pharma pricing and could prompt stronger responses from payers or regulators. Senior leaders in pharma and healthcare should monitor how these findings may affect reimbursement, access, and pricing negotiations.